6L6 Stock Overview
A medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Senseonics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.27 |
| 52 Week High | US$0.72 |
| 52 Week Low | US$0.25 |
| Beta | 0.80 |
| 11 Month Change | 3.82% |
| 3 Month Change | -13.41% |
| 1 Year Change | -40.66% |
| 33 Year Change | -91.95% |
| 5 Year Change | -72.45% |
| Change since IPO | -84.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6L6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -8.9% | -3.6% | -2.2% |
| 1Y | -40.7% | -3.5% | 13.3% |
Return vs Industry: 6L6 underperformed the German Medical Equipment industry which returned -2.7% over the past year.
Return vs Market: 6L6 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| 6L6 volatility | |
|---|---|
| 6L6 Average Weekly Movement | 17.4% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6L6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6L6's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 132 | Tim Goodnow | www.senseonics.com |
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company’s products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Senseonics Holdings, Inc. Fundamentals Summary
| 6L6 fundamental statistics | |
|---|---|
| Market cap | €181.55m |
| Earnings (TTM) | -€73.97m |
| Revenue (TTM) | €22.10m |
8.2x
P/S Ratio-2.4x
P/E RatioIs 6L6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6L6 income statement (TTM) | |
|---|---|
| Revenue | US$24.04m |
| Cost of Revenue | US$21.15m |
| Gross Profit | US$2.89m |
| Other Expenses | US$83.35m |
| Earnings | -US$80.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 12.04% |
| Net Profit Margin | -334.69% |
| Debt/Equity Ratio | 138.2% |
How did 6L6 perform over the long term?
See historical performance and comparison